我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
188
7 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
1
0.5%
已完成
146
77.7%
尚未招募
6
3.2%
招募中
32
17.0%
暂停
暂无批准数据
- The ibrutinib/venetoclax combination demonstrated an 83% objective response rate with sustained efficacy in Japanese patients with relapsed/refractory mantle cell lymphoma over 37 months of follow-up. - A novel frontline approach using acalabrutinib/rituximab followed by brexu-cel CAR-T therapy achieved 100% response rates in previously untreated high-risk MCL patients. - Both treatment strategies showed manageable safety profiles despite different toxicity patterns, with the CAR-T approach requiring intensive care in 40% of patients. - These findings suggest promising therapeutic options for MCL patients, addressing unmet medical needs in both relapsed/refractory and frontline high-risk settings.
